Summary

Eligibility
for people ages 30-80 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Marta San Luciano Palenzuela

Description

Summary

Official Title

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease

Details

BIIB122 is an investigational central nervous system-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2). Participants who completed the early termination (ET) visit of the study 283PD302 (NCT05418673) would be eligible for screening of this study and if enrolled, these participants are not eligible for the sub studies of 283PD201.

Keywords

Parkinson Disease, Early-stage Parkinson Disease, BIIB122, BIIB122 225 mg

Eligibility

Locations

  • UCSF (UCSF) accepting new patients
    San Francisco California 94143 United States
  • Cedars Sinai accepting new patients
    Los Angeles California 90048 United States
  • SC3 Research Group Inc. accepting new patients
    Pasadena California 91105 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Biogen
ID
NCT05348785
Phase
Phase 2 Parkinson's Disease Research Study
Study Type
Interventional
Participants
Expecting 640 study participants
Last Updated